New combo therapy shows promise for tough prostate cancers

NCT ID NCT03910660

Completed Disease control Sponsor: BioXcel Therapeutics Inc Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new drug (BXCL701) combined with an immunotherapy (pembrolizumab) in 98 men with advanced prostate cancer that no longer responds to hormone therapy. The goal was to see if the combination could shrink tumors or slow the disease. This is a disease control approach, not a cure, as ongoing treatment is needed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma metastatic prostate carcinoma neuroendocrine neoplasm prostate adenocarcinoma prostate cancer prostate small cell carcinoma small cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NEUROENDOCRINE TUMORS PROSTATE CANCER SMALL CELL CARCINOMA

Contacts and locations

Locations

BioXcel Clinical Research Site

Denver, Colorado, 80211, United States
BioXcel Clinical Research Site

Detroit, Michigan, 48201, United States
BioXcel Clinical Research Site

Glasgow, England, G12 0YN, United Kingdom
BioXcel Clinical Research Site

London, Great Britain, W1T 7HA, United Kingdom
BioXcel Clinical Research Site

Sutton, Surrey, SM2 5NG, United Kingdom
Center for Advanced Medicine / R.J. Zuckerberg Cancer Center (Northwell Health Cancer Institute)

Lake Success, New York, 11042, United States
Moffitt Cancer Center and Research Institute

Tampa, Florida, 33612, United States
The Ohio State University

Columbus, Ohio, 43210, United States
University of California San Francisco (UCSF)

San Francisco, California, 94158, United States
Weill Cornell Medicine New York

New York, New York, 10021, United States
White Plains Hospital Center for Cancer Care

White Plains, New York, 10601, United States
Yale University

New Haven, Connecticut, 06510, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.